MST
MCID: MYL058
MIFTS: 45

Myeloproliferative Syndrome, Transient (MST)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloproliferative Syndrome, Transient

MalaCards integrated aliases for Myeloproliferative Syndrome, Transient:

Name: Myeloproliferative Syndrome, Transient 57 73
Transient Myeloproliferative Syndrome 12 53 59 15
Transient Abnormal Myelopoiesis 57 12 53 59
Transient Myeloproliferative Disease 12 53 59
Mst 57 12
Tam 57 12
Tmd 53 59
Leukemia, Transient, of Down Syndrome 57
Transient Abnormal Myelopoiesis; Tam 57
Transient Leurkemia of Down Syndrome 12
Leukemia, Transient 57
Transient Leukemia 12

Characteristics:

Orphanet epidemiological data:

59
transient myeloproliferative syndrome
Inheritance: Not applicable; Age of onset: Antenatal,Neonatal; Age of death: infantile;

OMIM:

57
Inheritance:
possible disomic homozygosity at 21q11.2


Classifications:



External Ids:

OMIM 57 159595
Disease Ontology 12 DOID:0060888
ICD10 33 D47.7
Orphanet 59 ORPHA420611
UMLS via Orphanet 74 C1834582
ICD10 via Orphanet 34 D47.7
MedGen 42 C1834582
SNOMED-CT via HPO 69 111583006 450934005
UMLS 73 C1834582

Summaries for Myeloproliferative Syndrome, Transient

Disease Ontology : 12 A myeloproliferative neoplasm characterized by leukocytosis in newborns with Down syndrome and rarely in non-Down's infants.

MalaCards based summary : Myeloproliferative Syndrome, Transient, also known as transient myeloproliferative syndrome, is related to tibial muscular dystrophy, tardive and tibial muscular dystrophy. An important gene associated with Myeloproliferative Syndrome, Transient is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Alimta and Aloxi have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and lung, and related phenotypes are leukocytosis and transient myeloproliferative syndrome

Wikipedia : 76 Transient myeloproliferative disease (TMD) occurs in a significant percentage of individuals born with... more...

Description from OMIM: 159595

Related Diseases for Myeloproliferative Syndrome, Transient

Diseases in the 8p11 Myeloproliferative Syndrome family:

Myeloproliferative Syndrome, Transient Myeloproliferative Disease, Autosomal Recessive

Diseases related to Myeloproliferative Syndrome, Transient via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 tibial muscular dystrophy, tardive 11.6
2 tibial muscular dystrophy 11.5
3 myopathy, tubular aggregate, 1 11.4
4 ring dermoid of cornea 10.7
5 bruxism 10.4
6 megakaryocytic leukemia 10.3
7 joint disorders 10.3
8 breast cancer 10.2
9 gastric cancer 10.2
10 fetal and neonatal alloimmune thrombocytopenia 10.1 GP1BA ITGB3
11 spotted fever 10.1
12 autosomal dominant macrothrombocytopenia 10.1 GP1BA ITGB3
13 liver disease 10.1
14 hemopericardium 10.1
15 pericardial effusion 10.1
16 chromosomal triplication 10.1
17 neonatal leukemia 10.1 GATA1 PTPN11
18 myelophthisic anemia 10.1 CD33 PTPN11
19 inherited blood coagulation disease 10.1 GP1BA ITGB3
20 lymphocytic leukemia 10.1
21 anxiety 10.1
22 headache 10.1
23 primary thrombocytopenia 10.1 GP1BA ITGB3
24 autoimmune disease of blood 10.1 GP1BA ITGB3
25 pulmonary fibrosis, idiopathic 10.1
26 pulmonary fibrosis 10.1
27 adenocarcinoma 10.1
28 glioma 10.1
29 hypoxia 10.1
30 coronary thrombosis 10.1 GP1BA ITGB3
31 thrombocytopenia 10.1 GATA1 GP1BA ITGB3
32 arteritic anterior ischemic optic neuropathy 10.0 GP1BA ITGB3
33 essential thrombocythemia 10.0 GATA1 GP1BA ITGB3
34 bone marrow cancer 10.0 GATA1 ITGB3 PTPN11
35 alexithymia 10.0
36 whiplash 10.0
37 von willebrand disease, type 2 10.0 ITGB3 GP1BA
38 renal cell carcinoma, nonpapillary 10.0
39 osteogenic sarcoma 10.0
40 myocardial infarction 10.0
41 inguinal hernia 10.0
42 substance abuse 10.0
43 rhabdomyosarcoma 10.0
44 clear cell renal cell carcinoma 10.0
45 autoimmune disease 10.0
46 systemic lupus erythematosus 10.0
47 lung cancer susceptibility 3 10.0
48 lupus erythematosus 10.0
49 leukemia, acute lymphoblastic 10.0
50 noonan syndrome 1 10.0

Graphical network of the top 20 diseases related to Myeloproliferative Syndrome, Transient:



Diseases related to Myeloproliferative Syndrome, Transient

Symptoms & Phenotypes for Myeloproliferative Syndrome, Transient

Symptoms via clinical synopsis from OMIM:

57
Lab:
leukocytosis

Misc:
usually in newborns with down syndrome
rarely in normals

Heme:
transient myeloproliferative syndrome


Clinical features from OMIM:

159595

Human phenotypes related to Myeloproliferative Syndrome, Transient:

32
# Description HPO Frequency HPO Source Accession
1 leukocytosis 32 HP:0001974
2 transient myeloproliferative syndrome 32 HP:0005534

MGI Mouse Phenotypes related to Myeloproliferative Syndrome, Transient:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.65 ADM DIO3 FBXO43 GATA1 GFER GP1BA
2 liver/biliary system MP:0005370 9.17 ADM DIO3 GATA1 GFER ITGB3 MSTN

Drugs & Therapeutics for Myeloproliferative Syndrome, Transient

FDA approved drugs:

(show all 49)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
2
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
3
Anexsia 18 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
4
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
7
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
8
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
9
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
10
Femara 18 49 LETROZOLE Novartis January 2001
11
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
12
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
13
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
14
Jevtana 18 49 CABAZITAXEL sanofi aventis June 2010
15
Kytril 18 GRANISETRON HYDROCHLORIDE Roche/SmithKline Beecham June 2001/ November 1997
16
Miraluma Test 18 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
17
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
18
Plenaxis 18 ABARELIX Praecis Pharmaceuticals December 2003
19
Sancuso 18 GRANISETRON ProStrakan September 2008
20
Sensipar 18 CINACALCET HYDROCHLORIDE Amgen March 2004
21
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
22
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
23
Synercid I.V. 18 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
24
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
25
Tykerb 18 49 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
26
UroXatral 18 ALFUZOSIN HYDROCHLORIDE Sanofi-aventis June 2003
27
Xtandi 18 49 ENZALUTAMIDE Medivation August 2012
28
Zaltrap 18 49 ZIV-AFLIBERCEPT Sanofi-aventis August 2012
29
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
30
Aldurazyme 18 LARONIDASE Genzyme May 2003
31
Allegra 18 FEXOFENADINE HYDROCHLORIDE Hoechst Marion Roussel July 1996
32
Arnuity Ellipta 18 FLUTICASONE FUROATE GlaxoSmithKline August 2014
33
Augmentin 18 AMOXICILLIN; CLAVULANATE POTASSIUM SmithKline Beecham February 1996
34
Avelox I.V. 18 MOXIFLOXACIN HYDROCHLORIDE Bayer November 2001
35
Cayston 18 AZTREONAM Gilead February 2010
36
Cedax 18 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
37
Clarinex 18 DESLORATADINE Schering-Plough February 2002
38
Claritin-D 24 Hour Extended Release Tablets 18 LORATADINE; PSEUDOEPHEDRINE SULFATE Schering-Plough August 1996
39
DuoNeb 18 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
40
Dymista 18 AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE Meda Pharmaceuticals Inc May 2012
41
Invanz 18 ERTAPENEM SODIUM Merck November 2001
42
Oralair 18 Greer Labs April 2014
43
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008
44
Rhinocort Aqua Nasal Spray 18 BUDESONIDE AstraZeneca October 1999
45
Tygacil 18 TIGECYCLINE Wyeth 2005
46
Xolair 18 OMALIZUMAB Genentech June 2003
47
Xyzal 18 LEVOCETIRIZINE DIHYDROCHLORIDE UCB May 2007
48
Zosyn 18 PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Wyeth May 1996
49
Zyrtec 18 CETIRIZINE HYDROCHLORIDE Pfizer December 1995

Drugs for Myeloproliferative Syndrome, Transient (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
2
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
3
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
4
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
5
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
6
Thioguanine Approved Phase 3 154-42-7 2723601
7
Daunorubicin Approved Phase 3 20830-81-3 30323
8
Miconazole Approved, Investigational, Vet_approved Phase 3,Not Applicable 22916-47-8 4189
9
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
10
Vidarabine Approved, Investigational Phase 3,Phase 2,Not Applicable 24356-66-9 32326 21704
11
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
12
Fludarabine Approved Phase 3,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
13
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492
14
Mycophenolic acid Approved Phase 3,Not Applicable 24280-93-1 446541
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
16 Antimetabolites Phase 3,Phase 2,Not Applicable
17 Immunologic Factors Phase 3,Phase 2,Not Applicable
18 Hydrocortisone-17-butyrate Phase 3
19
asparaginase Phase 3
20 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
22 Folic Acid Antagonists Phase 3,Phase 2
23 Vitamin B9 Phase 3,Phase 2
24 Vitamin B Complex Phase 3,Phase 2
25 Anti-Bacterial Agents Phase 3,Not Applicable
26 Dermatologic Agents Phase 3,Phase 2,Not Applicable
27 Anti-Inflammatory Agents Phase 3
28 Hydrocortisone 17-butyrate 21-propionate Phase 3
29 Topoisomerase Inhibitors Phase 3
30 Antiviral Agents Phase 3,Phase 2,Not Applicable
31 Folate Phase 3,Phase 2
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
33 Antibiotics, Antitubercular Phase 3,Not Applicable
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
35 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
36 Cortisol succinate Phase 3
37 Antineoplastic Agents, Alkylating Phase 3,Phase 2
38 Cyclosporins Phase 3,Not Applicable
39 Vidarabine Phosphate Phase 3,Not Applicable
40 Alkylating Agents Phase 3,Phase 2
41 Antifungal Agents Phase 3,Not Applicable
42 Antitubercular Agents Phase 3,Not Applicable
43 Calcineurin Inhibitors Phase 3,Phase 2,Not Applicable
44
Promethazine Approved, Investigational Phase 2 60-87-7 4927
45
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
46
Acetaminophen Approved Phase 2 103-90-2 1983
47
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
48
Benzyl alcohol Approved Phase 2 100-51-6 244
49
Ethanol Approved Phase 2 64-17-5 702
50 Antilymphocyte Serum Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
2 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
3 Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder Withdrawn NCT00411281 Phase 3 cytarabine
4 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
5 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
6 INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed NCT01164163 Phase 1 ruxolitinib phosphate
7 Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder Completed NCT01511575
8 Study of Blood Samples From Newborns With Down Syndrome Active, not recruiting NCT00959283
9 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Myeloproliferative Syndrome, Transient

Genetic Tests for Myeloproliferative Syndrome, Transient

Anatomical Context for Myeloproliferative Syndrome, Transient

MalaCards organs/tissues related to Myeloproliferative Syndrome, Transient:

41
Bone, Myeloid, Lung, Kidney, Thyroid, T Cells, Bone Marrow

Publications for Myeloproliferative Syndrome, Transient

Articles related to Myeloproliferative Syndrome, Transient:

# Title Authors Year
1
Transient myeloproliferative syndrome associated with Down syndrome. ( 23084883 )
2013
2
Clinicopathological features of transient myeloproliferative syndrome and congenital leukaemia. ( 20810047 )
2010
3
Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: a case report and literature review. ( 12661826 )
2003
4
Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia. ( 11902730 )
2002
5
Lineage-specific trisomy 21 in a neonate with resolving transient myeloproliferative syndrome. ( 11990311 )
2002
6
Possible mapping of the gene for transient myeloproliferative syndrome at 21q11.2. ( 1680787 )
1991
7
Down's syndrome with transient myeloproliferative syndrome. ( 2147168 )
1990
8
Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. ( 2525515 )
1989
9
Transient myeloproliferative syndrome in a phenotypically normal infant. ( 4037246 )
1985

Variations for Myeloproliferative Syndrome, Transient

Expression for Myeloproliferative Syndrome, Transient

Search GEO for disease gene expression data for Myeloproliferative Syndrome, Transient.

Pathways for Myeloproliferative Syndrome, Transient

Pathways related to Myeloproliferative Syndrome, Transient according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.2 CD33 GP1BA ITGB3
2 10.79 CD33 GP1BA ITGB3

GO Terms for Myeloproliferative Syndrome, Transient

Biological processes related to Myeloproliferative Syndrome, Transient according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.5 GATA1 GP1BA ITGB3
2 homeostasis of number of cells within a tissue GO:0048873 9.26 GATA1 PTPN11
3 platelet formation GO:0030220 9.16 GATA1 PTPN11
4 platelet activation GO:0030168 9.13 GP1BA ITGB3 PTPN11
5 platelet aggregation GO:0070527 8.8 GATA1 GP1BA ITGB3

Sources for Myeloproliferative Syndrome, Transient

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....